Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.55 |
| ▸ | NEK2 | P51955 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390764 | 0.89 | GPR119 (0.72) | GPR119 | |
| SCHEMBL1673697 | 0.85 | GPR119 (0.53) | GPR119 | |
| SCHEMBL5261880 | 0.84 | GPR119 (0.57) | GPR119 | |
| SCHEMBL27631863 | 0.82 | GPR119 (0.62) | GPR119SCN9APDE10ARHOA | |
| SCHEMBL27631857 | 0.82 | GPR119 (0.62) | GPR119SCN9APDE10ARHOA | |
| SCHEMBL28757298 | 0.82 | GPR119 (0.67) | GPR119NEK2PDE10ARHOA | |
| SCHEMBL27747820 | 0.80 | GPR119 (0.79) | GPR119RHOA | |
| SCHEMBL27652250 | 0.80 | GPR119 (0.60) | GPR119RHOA | |
| SCHEMBL27631842 | 0.79 | GPR119 (0.70) | GPR119NEK2PDE10ARHOA | |
| SCHEMBL4763133 | 0.78 | GPR119 (0.57) | GPR119NEK2PDE10ARHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| CN-1835943-A | 1,2, 3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of diseases related thereto, such as diabetes and hyperglycemia | ARENA PHARM INC (US) | 2006-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | GPR119 2/4885NEK2 4685/4885SCN9A 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.